WO2004007743A3 - Use of cpg nucleic acids in prion-disease - Google Patents

Use of cpg nucleic acids in prion-disease Download PDF

Info

Publication number
WO2004007743A3
WO2004007743A3 PCT/IB2003/003727 IB0303727W WO2004007743A3 WO 2004007743 A3 WO2004007743 A3 WO 2004007743A3 IB 0303727 W IB0303727 W IB 0303727W WO 2004007743 A3 WO2004007743 A3 WO 2004007743A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
prion
disease
cpg nucleic
methods
Prior art date
Application number
PCT/IB2003/003727
Other languages
French (fr)
Other versions
WO2004007743A2 (en
Inventor
Hermann Wagner
Hans Kretzschmar
Shneh Sethi
Original Assignee
Coley Pharm Gmbh
Hermann Wagner
Hans Kretzschmar
Shneh Sethi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Gmbh, Hermann Wagner, Hans Kretzschmar, Shneh Sethi filed Critical Coley Pharm Gmbh
Priority to AU2003255969A priority Critical patent/AU2003255969A1/en
Publication of WO2004007743A2 publication Critical patent/WO2004007743A2/en
Publication of WO2004007743A3 publication Critical patent/WO2004007743A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods are provided which are useful in the treatment of prion diseases and other protein deposit diseases, including, for example, post-exposure prophylaxis against the development of iatrogenic Creutzfeldt-Jakob disease. The methods involve the use of immunostimulatory nucleic acids, including CpG nucleic acids.
PCT/IB2003/003727 2002-07-17 2003-07-17 Use of cpg nucleic acids in prion-disease WO2004007743A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003255969A AU2003255969A1 (en) 2002-07-17 2003-07-17 Use of cpg nucleic acids in prion-disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39643202P 2002-07-17 2002-07-17
US60/396,432 2002-07-17

Publications (2)

Publication Number Publication Date
WO2004007743A2 WO2004007743A2 (en) 2004-01-22
WO2004007743A3 true WO2004007743A3 (en) 2004-03-04

Family

ID=30116027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/003727 WO2004007743A2 (en) 2002-07-17 2003-07-17 Use of cpg nucleic acids in prion-disease

Country Status (2)

Country Link
AU (1) AU2003255969A1 (en)
WO (1) WO2004007743A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354522B2 (en) 2005-11-25 2013-01-15 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CA2419894A1 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Process for high throughput screening of cpg-based immuno-agonist/antagonist
WO2003015711A2 (en) 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity
CA2480775C (en) 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
CN1753687A (en) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
SG122973A1 (en) 2003-10-30 2006-06-29 Coley Pharm Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
KR100958505B1 (en) 2004-07-18 2010-05-17 씨에스엘 리미티드 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
JP2009507848A (en) * 2005-09-09 2009-02-26 オレゴン ヘルス アンド サイエンス ユニバーシティ Neuroprotective drugs
WO2007030580A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US9370531B2 (en) * 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO2001053457A2 (en) * 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
WO2001055386A1 (en) * 2000-01-25 2001-08-02 Glaxosmithkline Toll-like receptor
US20020064515A1 (en) * 1998-04-03 2002-05-30 Krieg Arthur M. Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
WO2003015711A2 (en) * 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20020064515A1 (en) * 1998-04-03 2002-05-30 Krieg Arthur M. Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2001053457A2 (en) * 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
WO2001055386A1 (en) * 2000-01-25 2001-08-02 Glaxosmithkline Toll-like receptor
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
WO2003015711A2 (en) * 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARLSON G A: "Postexposure prophylaxis against trans-missible spongiform encephalopathies: CpG oligodeoxynucleotides in mice", LANCET, XX, XX, vol. 360, no. 9328, 20 July 2002 (2002-07-20), pages 184, XP004371853, ISSN: 0140-6736 *
LEE I Y ET AL: "Complete genomic sequence and analysis of the prion protein gene region from three mammalian species.", GENOME RESEARCH. UNITED STATES OCT 1998, vol. 8, no. 10, October 1998 (1998-10-01), pages 1022 - 1037, XP002143521, ISSN: 1088-9051 *
O'NEILL L A J: "Toll-like receptor signal transduction and the tailoring of innate immunity: a role for Mal?", TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 23, no. 6, 1 June 2002 (2002-06-01), pages 296 - 300, XP004365773, ISSN: 1471-4906 *
PRINZ MARCO ET AL: "Prion pathogenesis in the absence of Toll-like receptor signalling.", EMBO REPORTS. ENGLAND FEB 2003, vol. 4, no. 2, February 2003 (2003-02-01), pages 195 - 199, XP009023514, ISSN: 1469-221X *
SETHI S ET AL: "Postexposure prophylaxis against prion disease with a stimulator of innate immunity", LANCET, XX, XX, vol. 360, no. 9328, 20 July 2002 (2002-07-20), pages 229 - 230, XP004371866, ISSN: 0140-6736 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354522B2 (en) 2005-11-25 2013-01-15 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Also Published As

Publication number Publication date
WO2004007743A2 (en) 2004-01-22
AU2003255969A8 (en) 2004-02-02
AU2003255969A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
WO2005027966A3 (en) Antibodies with altered effector functions
WO2004113277A3 (en) Methods and compositions for treating amyloid-related diseases
AU2003232061A1 (en) Database replication system
AU2002338265A1 (en) Molecules for disease detection and treatment
AU2001244609A1 (en) Novel protein, dna thereof and process for producing the same
AU2003279526A1 (en) Identifying and treating vaginal infections
WO2003005880A3 (en) Replikin peptides and uses thereof
WO2003063576A3 (en) Arylsulfonamidobenzylic compounds
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
AU2002329784A1 (en) Molecules for disease detection and treatment
AU2003298719A1 (en) Treatment for sma disease
AU2001263236A1 (en) Human myd88 adapter-like protein and functional fragments thereof
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2003219857A1 (en) Process for treating disease
AU2002306600A1 (en) Sperm protein 17 for the diagnosis and treatment of cancer
AU2002364890A1 (en) Molecules for disease detection and treatment
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
AU2003205174A1 (en) Molecules for disease detection and treatment
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
AU2002243539A1 (en) Molecules for disease detection and treatment
AU2002347899A1 (en) Molecules for disease detection and treatment
AU2002359310A1 (en) Treating diseases mediated by metalloprotease-shed proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP